EpiCept Corporation, a specialty pharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products for the treatment of pain and cancer. Its lead oncology compound, Ceplene, which is used for acute myeloid leukemia is in a Phase III trial. The company’s late-stage analgesic candidates include EpiCept NP-1 Cream, a prescription topical analgesic cream designed to provide relief from the pain of peripheral neuropathies; LidoPAIN SP, which is designed to provide topical delivery of lidocaine to a post surgical or post-traumatic sutured wound; and LidoPAIN BP, a prescription analgesic, designed to provide topical delivery of lidocaine for...